絞り込み

16645

広告

【動画】「cough medicine」を説明してみよう (日経BP)

診察室やカンファレンスなどでよく使う医療英語のエッセンスを、今日も楽しく学んでいきましょう。 今日のレッスンも「説明力トレーニング」です。「この薬って何ですか?...

  1. 入学定員減は 医学生の学力低下が背景に?...
  2. 心電図の新たな名著になるかもしれない書籍...
  3. マスクが足りない!医療機関でも深刻な事態...
  4. 新型コロナウイルス対応まっただ中の保健所...

ニュース一覧

Impact of choice of treatment for bleeding episodes on inhibitor outcome in patients with mild/moderate hemophilia a and inhibitors.

著者 d'Oiron R , Volot F , Reynaud J , Peerlinck K , Goudemand J , Guérois C , Rothschild C , Chambost H , Borel-Derlon A , Roussel-Robert V , Marquès-Verdier A , Lienhart A , Berthier AM , Moreau P , Lambert T ,
Semin Hematol.2006 Jan ; 43(1 Suppl 1):S3-9.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

Hemophilia Center, APHP Bicêtre University Hospital, Le Kremlin-Bicêtre, France. rosaline.doiron@bct.ap-hop-paris.fr

スターを付ける スターを付ける     (34view , 0users)

Full Text Sources

Medical

Patients with mild/moderate hemophilia A (MHA) may develop inhibitors to factor VIII (FVIII). In this condition, FVIII clotting activity (FVIII:C) baseline levels may remain stable for some patients, but may be reduced to less than 0.01 U/mL for others. Several risk factors for the development of inhibitors in MHA have been proposed. Genetic factors, such as mutations in the FVIII gene, may play a central role; however, other influences, such as intensive treatment with FVIII products, may also be important. Optimal treatment regimens have yet to be determined, not only for the eradication of inhibitors, but also for the management or surgical prophylaxis of hemorrhages associated with this condition. Several treatment options for the control of bleeding in patients with MHA and inhibitors (MHAI) are currently available, and the choice of therapeutic strategy should be given careful consideration; some treatments may produce an anamnestic response, thus delaying the return to FVIII:C baseline levels and adversely affecting the duration of the severe bleeding phenotype. To increase our knowledge of MHAI, a retrospective collection of data is currently being performed among hemophilia centers in France and Belgium. Based on five examples of patients with MHAI collated from preliminary study data, we illustrate the impact on inhibitor outcome of the therapeutic choices used to treat bleeding episodes in these patients.
PMID: 16427382 [PubMed - indexed for MEDLINE]
印刷用ページを開く Endnote用テキストダウンロード